Normal daily doses of rivaroxaban (15 to 20 mg) are linked to triple the risk of intracerebral hemorrhage (ICH) when compared to aspirin, according to a meta-analysis of five randomized trials published Aug. 13 in JAMA Neurology.

New research published in the European Heart Journal highlights how overall cerebrovascular disease deaths in Europe have declined. But that improvement has leveled off in some EU countries.

Originally thought to be a benign condition, Takotsubo syndrome is associated with long-term outcomes similar to acute coronary syndrome (ACS), researchers reported in the Journal of the American College of Cardiology. And in cases where Takotsubo syndrome (TTS) is triggered by physical events, prognosis is even worse.

Patients who were prescribed a single pill with low doses of three antihypertensive medications reached their blood pressure (BP) targets more often than those following a usual care plan, according to a randomized trial of 700 individuals from the Sri Lankan public health system.

Revascularization techniques to treat primary critical limb ischemia (CLI) may be more cost-effective and associated with longer survival than primary major amputation, according to new research published in the Journal of the American Heart Association.

Experimental gene therapies to treat hemophilia are still undergoing testing, but early results from clinical trials have both researchers and patients optimistic the condition can be cured once and for all.

Maintaining an optimal body mass index (BMI), in addition to controlling other cardiovascular risk factors, may reduce the risk of peripheral artery disease (PAD) with critical limb ischemia (CLI), according to new research in the Journal of the American Heart Association.

The factor Xa inhibitor edoxaban might reduce the risk of several adverse events—including stroke, major bleeding and all-cause death—when compared to warfarin, according to a real-world study of Korean patients with atrial fibrillation (AFib).